# Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

> **NCT00060372** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 21 (actual)

## Conditions studied

- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Childhood Myelodysplastic Syndromes
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Disseminated Neuroblastoma
- Malignant Neoplasm
- Ovarian Choriocarcinoma
- Ovarian Embryonal Carcinoma
- Ovarian Immature Teratoma
- Ovarian Mature Teratoma
- Ovarian Mixed Germ Cell Tumor
- Ovarian Monodermal and Highly Specialized Teratoma
- Ovarian Polyembryoma
- Ovarian Yolk Sac Tumor
- Previously Treated Myelodysplastic Syndromes
- Recurrent Adult Acute Lymphoblastic Leukemia
- Recurrent Adult Acute Myeloid Leukemia
- Recurrent Adult Burkitt Lymphoma
- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Adult Diffuse Mixed Cell Lymphoma
- Recurrent Adult Hodgkin Lymphoma
- Recurrent Adult Immunoblastic Large Cell Lymphoma
- Recurrent Adult Lymphoblastic Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Malignant Testicular Germ Cell Tumor
- Recurrent Mantle Cell Lymphoma
- Recurrent Neuroblastoma
- Recurrent Ovarian Epithelial Cancer
- Recurrent Ovarian Germ Cell Tumor
- Refractory Chronic Lymphocytic Leukemia
- Refractory Multiple Myeloma
- Relapsing Chronic Myelogenous Leukemia
- Stage I Multiple Myeloma
- Stage II Multiple Myeloma
- Stage II Ovarian Epithelial Cancer
- Stage III Malignant Testicular Germ Cell Tumor
- Stage III Multiple Myeloma
- Stage III Ovarian Epithelial Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer
- Stage IV Ovarian Epithelial Cancer
- Testicular Choriocarcinoma
- Testicular Choriocarcinoma and Embryonal Carcinoma
- Testicular Choriocarcinoma and Seminoma
- Testicular Choriocarcinoma and Teratoma
- Testicular Choriocarcinoma and Yolk Sac Tumor
- Testicular Embryonal Carcinoma
- Testicular Embryonal Carcinoma and Seminoma
- Testicular Embryonal Carcinoma and Teratoma
- Testicular Embryonal Carcinoma and Teratoma With Seminoma
- Testicular Embryonal Carcinoma and Yolk Sac Tumor
- Testicular Embryonal Carcinoma and Yolk Sac Tumor With Seminoma
- Testicular Teratoma
- Testicular Yolk Sac Tumor
- Testicular Yolk Sac Tumor and Teratoma
- Testicular Yolk Sac Tumor and Teratoma With Seminoma

## Interventions

- **DRUG:** ipilimumab
- **DRUG:** therapeutic allogeneic lymphocytes

## Key facts

- **NCT ID:** NCT00060372
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2008-04
- **Final completion:** —
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2013-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00060372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00060372, "Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00060372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*